Biocartis
Biocartis H1 Revenues up 31 Percent
The revenue growth was driven by sales of the company's Idylla molecular diagnostics system and related test cartridges.
Biocartis Receives €1.4M Grant to Develop New Technology for Molecular Surveillance
The grant will support development of next-generation technology for the firm's Idylla platform that would allow for the offline customization of cartridges.
Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test
The Belgian molecular diagnostics firm also reported a 70 percent year-over-year increase in commercial cartridge volumes in the first quarter.
Biocartis Files FDA Submission for Microsatellite Instability Test in Colorectal Cancer
The assay is intended to detect
Biocartis Reports 15 Percent Rise in 2020 Revenues
For the 12 months ended Dec. 31, 2020, Biocartis' revenues rose to €43.1 million ($52.7 million) from €37.4 million in 2019.
Nov 12, 2020
Biocartis Q3 Cartridge Volume Grows 61 Percent
Nov 10, 2020
Biocartis Gets CE Mark for SARS-CoV-2 RT-PCR Test
Sep 3, 2020
Biocartis H1 Revenues Drop 2 Percent
Sep 5, 2019